The global demand for Sarcopenia Treatment Market in terms of revenue was worth of USD 262.9 Million in 2020 and is expected to reach USD 377.6 Million in 2027, growing at a CAGR of 5.87% from 2021 to 2027.
Sarcopenia is the loss of muscle mass due to the natural ageing process. According to the International Osteoporosis Foundation (IOF), muscle loss starts from the age of 40. Sarcopenia can have an effect on a person’s ability to perform everyday activities, such as walking, climbing stairs and lifting objects. The decrease in muscle leads to a person's strength.
Treatment and future perspectives Sarcopenia is treated currently with pharmacologic treatment and lifestyle interventions. Currently, there are no FDA-approved medications for the treatment of sarcopenia because of which treatment comprises of various supplements such as creatine, protein ammonia acid, omega 3 acid, B12, and calcium carbonate.
Sarcopenia is the loss of muscle mass due to the natural ageing process. According to the International Osteoporosis Foundation (IOF), muscle loss starts from the age of 40. Sarcopenia can have an effect on a person’s ability to perform everyday activities, such as walking, climbing stairs and lifting objects. The decrease in muscle leads to a person's strength.
Treatment and future perspectives Sarcopenia is treated currently with pharmacologic treatment and lifestyle interventions. Currently, there are no FDA-approved medications for the treatment of sarcopenia because of which treatment comprises of various supplements such as creatine, protein ammonia acid, omega 3 acid, B12, and calcium carbonate.
- Aerospace and Defense
- Agriculture
- Automotive and Transportation
- Business and Finance
- Chemical and Materials
- Consumer Goods and Retails
- Electronics and Semiconductor
- Energy and Power
- Food and Beverages
- Machinery and Equipment
- Manufacturing and Construction
- Medical Devices
- Pharmaceuticals and Healthcare
- Service and Software
- Technology, Media and Telecommunications
- Travel and Tourism
